(VIANEWS) – MERCK AND CO INC (MRK.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MERCK AND CO INC (MRK.PA) | €101.40 | 2.61% | 29.69% |
| ESSILORLUXOTTICA (EL.PA) | €177.48 | 1.75% | 6.16% |
| BIOMERIEUX (BIM.PA) | €98.96 | 0.91% | 12.95% |
| SARTORIUS STED BIO (DIM.PA) | €282.00 | 0.61% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MERCK AND CO INC (MRK.PA)
2.61% Forward Dividend Yield and 29.69% Return On Equity
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.82.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 21.04. Meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Moving Average
MERCK AND CO INC’s value is under its 50-day moving average of €103.30 and higher than its 200-day moving average of €99.53.
More news about MERCK AND CO INC.
2. ESSILORLUXOTTICA (EL.PA)
1.75% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.84.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 36.67. Meaning, the purchaser of the share is investing €36.67 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
More news about ESSILORLUXOTTICA.
3. BIOMERIEUX (BIM.PA)
0.91% Forward Dividend Yield and 12.95% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.82.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 25.91. Meaning, the purchaser of the share is investing €25.91 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.95%.
More news about BIOMERIEUX.
4. SARTORIUS STED BIO (DIM.PA)
0.61% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €8.03.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 35.12. Meaning, the purchaser of the share is investing €35.12 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was 0.69%, 1.74%, and 2.10%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 1.13% (last week), 2.22% (last month), and 2.10% (last quarter).
More news about SARTORIUS STED BIO.
